HER2 測試市場報告：2030 年趨勢、預測與競爭分析

HER2 檢測趨勢與預測

預計 2024 年至 2030 年，全球 HER2 檢測市場將以 7.1% 的複合年成長率成長。該市場的主要驅動力是個人化醫療方法的日益重要以及乳癌和胃癌盛行率的迅速增加。全球 HER2 檢測市場的未來前景廣闊，醫院和診斷實驗室市場充滿機會。

分段 HER2 測試

該研究包括按技術、癌症類型、最終用途和地區對全球 HER2 檢測的預測。

HER2 測試市場洞察

Lucintel 預測，由於其成本效益和快速週轉時間，螢光原位雜合反應(FISH) 在預測期內仍將是最大的細分市場。

由於專業醫療設備和基礎設施的可用性，醫院可能仍然是該市場中最大的部分。

北美乳癌盛行率很高，在預測期內可能仍然是最大的地區。

常問問題

Q1.市場成長預測是多少：

A1.全球HER2 檢測市場預估 2024 年至 2030 年複合年成長率為 7.1%。

Q2. 影響市場成長的關鍵促進因素是：

A2. 該市場的主要驅動力是個人化醫療方法的日益重要以及乳癌和胃癌盛行率的迅速增加。

Q3.市場的主要細分市場是：

A3.HER2 檢測市場的未來看起來充滿希望，醫院和診斷實驗室市場也充滿機會。

Q4.市場的主要企業是：

A4. HER2檢測主要企業如下：

• Abbott
• Hoffmann-La Roche
• Agilent Technologies
• Thermo Fisher Scientific
• Leica Biosystems
• Empire Genomics
• Bio-Genex Laboratories

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計螢光原位雜合反應(FISH) 由於其成本效益和快速週轉時間，在預測期內仍將是最大的細分市場。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 由於乳癌盛行率較高，北美在預測期內仍是最大的地區。

Q7. 可以客製化報告嗎？

A7。

目錄

第1章執行摘要

第2章全球HER2 檢測市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球 HER2 檢測市場趨勢（2018-2023）與預測（2024-2030）
• HER2 技術檢測的全球市場
  • 螢光原位雜合反應（FISH）
  • 雙探頭
  • 單探頭
  • 顯色雜合反應(CISH)
  • 銀敏原位雜合反應
• 以癌症類型分類的 HER2 檢測的全球市場
  • 乳癌
  • 胃癌
• 按最終用途分類的 HER2 測試全球市場
  • 醫院
  • 診斷實驗室
  • 其他

第4章 2018-2030年區域市場趨勢及預測分析

• 按地區分類的 HER2 檢測市場
• 北美HER2檢測市場
• 歐洲HER2檢測市場
• 亞太 HER2 測試市場
• 其他地區HER2檢測市場

第5章 競爭分析

• 產品系列分析
• 業務整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • HER2 檢測市場的技術成長機會
  • 按癌症類型分類的全球 HER2 檢測市場成長機會
  • 按最終用途分類的全球 HER2 測試市場成長機會
  • 全球 HER2 測試市場成長機會（按地區）
• 全球HER2檢測市場新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球 HER2 檢測市場的產能
  • 全球 HER2 檢測市場的合併、收購與合資
  • 認證和許可

第7章主要企業概況

• Abbott
• Hoffmann-La Roche
• Agilent Technologies
• Thermo Fisher Scientific
• Leica Biosystems
• Empire Genomics
• Bio-Genex Laboratories

HER2 Testing Trends and Forecast

The future of the global HER2 testing market looks promising with opportunities in the hospitals and diagnostic laboratories markets. The global HER2 testing market is expected to grow with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are increasing significance of personalized medical approaches and surge in the prevalence of breast and gastric cancers.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

HER2 Testing by Segment

The study includes a forecast for the global HER2 testing by technique, cancer type, end use, and region.

HER2 Testing Market by Technique [Shipment Analysis by Value from 2018 to 2030]:

• Fluorescence In Situ Hybridization
• Dual-Probe
• Single-Probe
• Chromogenic In Situ Hybridization
• Silver-Enhanced In Situ Hybridization

HER2 Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Breast Cancer
• Gastric Cancer

HER2 Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Diagnostic Laboratories
• Others

HER2 Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of HER2 Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies HER2 testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the HER2 testing companies profiled in this report include-

• Abbott
• Hoffmann-La Roche
• Agilent Technologies
• Thermo Fisher Scientific
• Leica Biosystems
• Empire Genomics
• Bio-Genex Laboratories

HER2 Testing Market Insights

Lucintel forecasts that fluorescence in situ hybridization will remain the largest segment over the forecast period due to their cost-effectiveness and faster turnaround times.

Within this market, hospitals will remain the largest segment due to availability of specialized medical equipment and infrastructure.

North America will remain the largest region over the forecast period due to high prevalence of breast cancer.

Features of the Global HER2 Testing Market

Market Size Estimates: HER2 testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: HER2 testing market size by technique, cancer type, end use, and region in terms of value ($B).

Regional Analysis: HER2 testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different techniques, cancer types, end uses, and regions for the HER2 testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the HER2 testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for HER2 testing market?

Answer: The global HER2 testing market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the HER2 testing market?

Answer: The major drivers for this market are increasing significance of personalized medical approaches and surge in the prevalence of breast and gastric cancers.

Q3. What are the major segments for HER2 testing market?

Answer: The future of the HER2 testing market looks promising with opportunities in the hospitals and diagnostic laboratories markets.

Q4. Who are the key HER2 testing market companies?

Answer: Some of the key HER2 testing companies are as follows:

• Abbott
• Hoffmann-La Roche
• Agilent Technologies
• Thermo Fisher Scientific
• Leica Biosystems
• Empire Genomics
• Bio-Genex Laboratories

Q5. Which HER2 testing market segment will be the largest in future?

Answer: Lucintel forecasts that fluorescence in situ hybridization will remain the largest segment over the forecast period due to their cost-effectiveness and faster turnaround times.

Q6. In HER2 testing market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of breast cancer.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the HER2 testing market by technique (fluorescence in situ hybridization, dual-probe, single-probe, chromogenic in situ hybridization, and silver-enhanced in situ hybridization), cancer type (breast cancer and gastric cancer), end use (hospitals, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global HER2 Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global HER2 Testing Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global HER2 Testing Market by Technique
  • 3.3.1: Fluorescence in situ hybridization
  • 3.3.2: Dual-probe
  • 3.3.3: Single-probe
  • 3.3.4: Chromogenic in situ hybridization
  • 3.3.5: Silver-enhanced in situ hybridization
• 3.4: Global HER2 Testing Market by Cancer Type
  • 3.4.1: Breast Cancer
  • 3.4.2: Gastric Cancer
• 3.5: Global HER2 Testing Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Diagnostic Laboratories
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global HER2 Testing Market by Region
• 4.2: North American HER2 Testing Market
  • 4.2.1: North American HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
  • 4.2.2: North American HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
• 4.3: European HER2 Testing Market
  • 4.3.1: European HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
  • 4.3.2: European HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
• 4.4: APAC HER2 Testing Market
  • 4.4.1: APAC HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
  • 4.4.2: APAC HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
• 4.5: ROW HER2 Testing Market
  • 4.5.1: ROW HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
  • 4.5.2: ROW HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global HER2 Testing Market by Technique
  • 6.1.2: Growth Opportunities for the Global HER2 Testing Market by Cancer Type
  • 6.1.3: Growth Opportunities for the Global HER2 Testing Market by End Use
  • 6.1.4: Growth Opportunities for the Global HER2 Testing Market by Region
• 6.2: Emerging Trends in the Global HER2 Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global HER2 Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global HER2 Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Hoffmann-La Roche
• 7.3: Agilent Technologies
• 7.4: Thermo Fisher Scientific
• 7.5: Leica Biosystems
• 7.6: Empire Genomics
• 7.7: Bio-Genex Laboratories